Drug Trial News

RSS

St. Michael's to investigate new treatments for prevention of brain injury complications

St. Michael's Hospital has been awarded up to $700,000 from the Federal Economic Development Agency of Southern Ontario to investigate new treatments to prevent complications following certain brain injuries.

16 Jun 2012

Large-scale trial of vaginal ring that releases anti-HIV drug announced at health summit in London

"This week, at the Pacific Health Summit in London, the final large-scale trial was officially launched of a vaginal ring which women can wear and forget about -- at least for a month at a time -- while it releases an HIV virus-killing drug called dapivirine," the Guardian reports.

16 Jun 2012

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., today announced six-year follow-up results from a Phase 3 randomised, open-label, dose-optimisation study of SPRYCEL (dasatinib) in Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid leukaemia (CP-CML) adult patients resistant or intolerant to Glivec (imatinib).

16 Jun 2012

Study finds no evidence to support an effect of THC on MS progression

The first large non-commercial study to investigate whether the main active constituent of cannabis (tetrahydrocannabinol or THC) is effective in slowing the course of progressive multiple sclerosis (MS) shows that there is no evidence to suggest this; although benefits were noted for those at the lower end of the disability scale.

16 Jun 2012

Civitas commences CVT-301 Phase 2a trial in Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today the initiation of a Phase 2a clinical trial in Parkinson's disease patients evaluating CVT-301, an inhaled formulation of levodopa (L-dopa), for the rapid relief from motor fluctuations.

16 Jun 2012

Less expensive ARV combination just as effective for women in developing countries as costlier ARVs, study shows

A new study by researchers at Brigham and Women's Hospital in Boston shows that the less-expensive antiretroviral nevirapine, when used in combination with other antiretroviral drugs (ARVs), is as effective as a more expensive combination among women in developing countries, VOA News reports.

16 Jun 2012

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Sanofi presented results from the landmark ORIGIN trial (Outcome Reduction with Initial Glargine Intervention) at the American Diabetes Association 72nd Scientific sessions. The key findings showed that, compared to standard care, Lantus(insulin glargine [rDNA] injection) had no statistically significant positive or negative impact on cardiovascular (CV) outcomes versus standard care during the study period and that there was no association between insulin glargine use and increased risk of any cancer.

15 Jun 2012

Changing guidelines threaten important HIV drug trial

In the battle against HIV/AIDS conditions on the frontlines are constantly in flux as treatment, research and policy evolve. The landmark HIV Prevention Trials Network (HPTN) 052 study, which established that antiretroviral treatment in people who are HIV positive decreases the likelihood of transmitting HIV to their sexual partners, was no exception.

15 Jun 2012

Positive top-line results from Teva’s GALA Phase III trial on RRMS

Teva Pharmaceutical Industries Ltd. today announced positive top-line results from the GALA (Glatiramer Acetate Low-Frequency Administration) Phase III clinical trial assessing the efficacy, safety and tolerability of 40 mg/1 ml glatiramer acetate injection (GA) administered subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis (RRMS) patients.

15 Jun 2012

TGen, Scottsdale Healthcare open INNO-206 Phase 2 trial for pancreatic cancer

An investigational drug that acts like a Trojan Horse to deliver cancer killing agents for pancreatic cancer is being studied at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) that treats cancer patients with promising new drugs.

15 Jun 2012

Antioxidant rhSOD reduces risk of blindness in extremely low gestational age newborns

Retinopathy of prematurity (ROP) is the second most common cause of childhood blindness in the United States, occurring in half of premature infants born earlier than or at 28 weeks gestational age. The condition is caused by abnormal blood vessel development in the retina of the eye. ROP risk increases with decreasing gestational age.

15 Jun 2012

Dyax to discontinue ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Dyax Corp. announced today the decision to discontinue the Company's Phase 2 trial investigating ecallantide in the acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema based upon the results of an interim analysis.

15 Jun 2012

Theraclone Sciences commences TCN-202 Phase 1 trial in CMV infection

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-202, a broadly protective, fully human monoclonal antibody in development for the treatment of human cytomegalovirus (CMV) infection.

15 Jun 2012

Quest receives FDA clearance to initiate oregovomab Phase II trial in ovarian cancer

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has received clearance from the United States Food and Drug Administration to initiate U.S. sites for an ongoing international Phase II clinical trial for oregovomab in advanced ovarian cancer patients.

15 Jun 2012

Hay fever vaccine shows efficacy in phase IIa trial

A novel vaccine for grass pollen allergy has shown significant improvements for patients in a Phase IIa trial. The vaccine BM32 is based on an innovative recombinant peptide carrier technology that allows for fewer injections and shows fewer side effects compared with other immunotherapy treatments for allergy sufferers. BM32 has been developed by Biomay AG, an Austrian biopharmaceutical company specialized in the discovery and development of innovative allergy therapeutics. The company has already initiated a Phase IIb trial for BM32 with 180 allergic patients.

14 Jun 2012

AB Science announces results from masitinib phase 2 study on MS

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announces the publication of results from the human phase 2 study of masitinib carried-out in the treatment of progressive multiple sclerosis.

14 Jun 2012

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced updated survival data from a pivotal Phase II clinical trial of single-agent brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplant (ASCT) showing that the median overall survival has not been reached after a 26.5 month median follow-up.

14 Jun 2012

Cancers often recur after treatment with single drugs that “target” tumor cells’ genetic pathways

Targeted cancer cell therapies using man-made proteins dramatically shrink many tumors in the first few months of treatment, but new research from Johns Hopkins scientists finds why the cells all too often become resistant, the treatment stops working, and the disease returns.

14 Jun 2012

IBBR, Sanaria to receive Phase II SBIR grant from NIAID for malaria vaccine

Sanaria Inc., a privately held company in Rockville, Maryland, and the Institute for Bioscience and Biotechnology Research (IBBR) of the University of Maryland College Park announce the receipt of a multi-year Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).

14 Jun 2012

Sabin initiates novel human hookworm vaccine Phase 1 clinical trial

Today, the Sabin Vaccine Institute, in partnership with the George Washington University and the Children's National Medical Center, began vaccinating participants for a Phase 1 clinical trial of a novel human hookworm vaccine.

14 Jun 2012

Drug Trial News

St. Michael's to investigate new treatments for prevention of brain injury complications

Large-scale trial of vaginal ring that releases anti-HIV drug announced at health summit in London

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Study finds no evidence to support an effect of THC on MS progression

Civitas commences CVT-301 Phase 2a trial in Parkinson's disease

Less expensive ARV combination just as effective for women in developing countries as costlier ARVs, study shows

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Changing guidelines threaten important HIV drug trial

Positive top-line results from Teva’s GALA Phase III trial on RRMS

TGen, Scottsdale Healthcare open INNO-206 Phase 2 trial for pancreatic cancer

Antioxidant rhSOD reduces risk of blindness in extremely low gestational age newborns

Dyax to discontinue ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Theraclone Sciences commences TCN-202 Phase 1 trial in CMV infection

Quest receives FDA clearance to initiate oregovomab Phase II trial in ovarian cancer

Hay fever vaccine shows efficacy in phase IIa trial

AB Science announces results from masitinib phase 2 study on MS

Updated survival data from Takeda’s brentuximab vedotin Phase II trial on HL

Cancers often recur after treatment with single drugs that “target” tumor cells’ genetic pathways

IBBR, Sanaria to receive Phase II SBIR grant from NIAID for malaria vaccine

Sabin initiates novel human hookworm vaccine Phase 1 clinical trial

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News